Bhadrasain Vikram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bhadrasain Vikram has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Chandan Guha
Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
5 shared publications A Alfieri
Department of Radiation Oncology, Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY, USA
2 shared publications- C. Norman Coleman
National Cancer Institute, Bethesda, MD
2 shared publications Ceferino Obcemea
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2 shared publicationsDavid Raben
Department of Radiation Oncology University of Colorado Denver School of Medicine Aurora Colorado
2 shared publications- Jacek Capala
National Cancer Institute, National Institutes of Health, Bethesda, USA
2 shared publications
Latest Publications
- Open Access
- 11 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (2) , 221-223
The NCI Glioblastoma Therapeutics Network (GTN)
Suzanne Forry, Leah Hubbard, Michael G Espey, Bhadrasain Vikram, Bhupinder Mann, Abdul Tawab-Amiri, Toby Hecht; The NCI Glioblastoma Therapeutics Network (GTN),
- 11 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (2) , 221-223
Open AccessThe NCI Glioblastoma Therapeutics Network (GTN)
Suzanne Forry, Leah Hubbard, Michael G Espey, Bhadrasain Vikram, Bhupinder Mann, Abdul Tawab-Amiri, Toby Hecht; The NCI Glioblastoma Therapeutics Network (GTN),
- Open Access
- 17 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care
In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.
- 17 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Open AccessMoving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care
In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.
- Open Access
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
Colorectal cancer (CRC) represents a major public health problem as the second leading cause of cancer‐related mortality in the United States. Of an estimated 140,000 newly diagnosed CRC cases in 2018, roughly one‐third of these patients will have a primary tumor located in the distal large bowel or rectum. The current standard‐of‐care approach includes curative‐intent surgery, often after preoperative (neoadjuvant) radiotherapy (RT), to increase rates of tumor down‐staging, clinical and pathologic response, as well as improving surgical resection quality. However, despite advancements in surgical techniques, as well as sharpened precision of dosimetry offered by contemporary RT delivery platforms, the oncology community continues to face challenges related to disease relapse. Ongoing investigations are aimed at testing novel radiosensitizing agents and treatments that might exploit the systemic antitumor effects of RT using immunotherapies. If successful, these treatments may usher in a new curative paradigm for rectal cancers, such that surgical interventions may be avoided. Importantly, this disease offers an opportunity to correlate matched paired biopsies, radiographic response, and molecular mechanisms of treatment sensitivity and resistance with clinical outcomes. Herein, the authors highlight the available evidence from preclinical models and early‐phase studies, with an emphasis on promising developmental therapeutics undergoing prospective validation in larger scale clinical trials. This review by the National Cancer Institute's Radiation Research Program Colorectal Cancer Working Group provides an updated, comprehensive examination of the continuously evolving state of the science regarding radiosensitizer drug development in the curative treatment of CRC.
Open AccessNational Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
Colorectal cancer (CRC) represents a major public health problem as the second leading cause of cancer‐related mortality in the United States. Of an estimated 140,000 newly diagnosed CRC cases in 2018, roughly one‐third of these patients will have a primary tumor located in the distal large bowel or rectum. The current standard‐of‐care approach includes curative‐intent surgery, often after preoperative (neoadjuvant) radiotherapy (RT), to increase rates of tumor down‐staging, clinical and pathologic response, as well as improving surgical resection quality. However, despite advancements in surgical techniques, as well as sharpened precision of dosimetry offered by contemporary RT delivery platforms, the oncology community continues to face challenges related to disease relapse. Ongoing investigations are aimed at testing novel radiosensitizing agents and treatments that might exploit the systemic antitumor effects of RT using immunotherapies. If successful, these treatments may usher in a new curative paradigm for rectal cancers, such that surgical interventions may be avoided. Importantly, this disease offers an opportunity to correlate matched paired biopsies, radiographic response, and molecular mechanisms of treatment sensitivity and resistance with clinical outcomes. Herein, the authors highlight the available evidence from preclinical models and early‐phase studies, with an emphasis on promising developmental therapeutics undergoing prospective validation in larger scale clinical trials. This review by the National Cancer Institute's Radiation Research Program Colorectal Cancer Working Group provides an updated, comprehensive examination of the continuously evolving state of the science regarding radiosensitizer drug development in the curative treatment of CRC.
- Open Access
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (9) , 2166-2170
Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint
The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (9) , 2166-2170
Open AccessWorkshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint
The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and
- 26 November 2006
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 81 (3) , 324-325
A core curriculum for RTTs (radiation therapists/radiotherapy radiographers) designed for developing countries under the auspices of the international atomic energy agency (IAEA)
- 26 November 2006
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 81 (3) , 324-325
A core curriculum for RTTs (radiation therapists/radiotherapy radiographers) designed for developing countries under the auspices of the international atomic energy agency (IAEA)
- Open Access
- 1 October 2002
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 54 (2) , 173
Radiation-enhanced in situ tumor vaccination for diffuse hepatocellular carcinoma: induction of tumor-specific immunity by systemic CD40-ligand and FLT3-Ligand gene therapy
- 1 October 2002
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 54 (2) , 173
Open AccessRadiation-enhanced in situ tumor vaccination for diffuse hepatocellular carcinoma: induction of tumor-specific immunity by systemic CD40-ligand and FLT3-Ligand gene therapy
- 1 November 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (3) , 105-106
A novel therapeutic strategy for hepatocellular carcinoma: immunomodulation by Flt3-Ligand (Flt3L) following whole liver irradiation and radio-inducible HSV-TK gene therapy
- 1 November 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (3) , 105-106
A novel therapeutic strategy for hepatocellular carcinoma: immunomodulation by Flt3-Ligand (Flt3L) following whole liver irradiation and radio-inducible HSV-TK gene therapy
- Open Access
- 1 November 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (3) , 181-182
Effect of ionizing radiation (IR) on expression of apoptosis related genes in a rat salivary gland derived cell line: implication of bcl-2 gene therapy in xerostomia
- 1 November 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (3) , 181-182
Open AccessEffect of ionizing radiation (IR) on expression of apoptosis related genes in a rat salivary gland derived cell line: implication of bcl-2 gene therapy in xerostomia
- Open Access
- 1 January 2000
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 48 (3) , 277-278
Adenovirus-mediated antisense ATM gene transfer radiosensitize prostate cancer to single and fractionated irradiation
- 1 January 2000
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 48 (3) , 277-278
Open AccessAdenovirus-mediated antisense ATM gene transfer radiosensitize prostate cancer to single and fractionated irradiation
- 1 January 2000
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 48 (3) , 284-285
Local irradiation and concomitant cytokines as an in situ autologous tumor vaccination strategy
- 1 January 2000
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 48 (3) , 284-285
Local irradiation and concomitant cytokines as an in situ autologous tumor vaccination strategy